Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II, Dose-escalation, Double-blinded, Placebo-controlled, and Dose-finding Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Osteoarthritis of the Knee

NCT05807529 is registered in ClinicalTrials.gov with Orient Europharma Co., Ltd. as lead sponsor.

NCT NCT05807529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05807529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II, Dose-escalation, Double-blinded, Placebo-controlled, and Dose-finding Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Osteoarthritis of the Knee
Lead sponsor
Orient Europharma Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 3, 2022
Completion date
December 31, 2024
Enrollment
136 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee